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The 1ubsfuuents at the various positions on the quinone-5,8-dione determine its activation 
by NQOl [NAD(P)H:quinone oxidoreductase 1], making the compound more toxic and specific 
towards NQOl-rich tumor cells. A series of reactions was conducted to synthesize the known 
?N-acetamido-2-formylquinoline-5,8-dione. The aldehyde group of this quinolone-5,8-dione was 
transformed into the corresponding oxime. The oxime derivative was oxidized to the nitrile oxide 
in situ with NaOCl (bleach) and produced an isoxazoline or isoxazole through 1 ,3-dipolar 
cycloaddition with alkenes or alkynes, respectively. Recrystallization and column 
chromatography were performed to purify the products. The percent yields of the novel oxime, 
isoxazoline and isoxazole were 52%, 59%, and 71%, respectively. Further tests will be 
conducted to study the toxicity and affinity of the oxime, isoxazoline, and isoxazole for NQO 1. 
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Author's Statement 
In the United States, cancer is the most common cause of death, exceeded only by heart 
disease, and accounts for nearly one of every four deaths. About 589,430 Americans were 
expected to die of cancer in 2015, or about 1,620 people per dar. The shocking figure does not 
stop there. It is estimated that approximately 1,658,370 new cancer cases were diagnosed in 
20152. This number does not include carcinoma in situ (noninvasive cancer) and basal cell skin 
cancers because they are not required to be reported to cancer registries. 
Despite its detrimental effects, many people are not fully aware of cancer. Cancer is not a 
disease, but a group of diseases characterized by the uncontrolled growth and spread of abnormal 
cells. If not treated, the spread can result in death. Cancer is caused by both external factors (such 
as tobacco, infectious organisms, and unhealthy diet) and internal factors (such as inherited 
genetic mutation, hormones, and immune conditions l While some cancers are curable, others 
require drugs to reduce symptoms and prolong survival. In 2004-2010, about 68% of cancer 
patients survived during the first five years of treatment, which is an improvement from 49% in 
1975-19772 . News drugs and therapies are discovered every year to accommodate the ever 
complex and increasing growth of cancer. With the new and improved drugs, millions of lives 
can be saved. However, the dilemma is how to synthesize drugs that are selectively toxic toward 
tumor cells but leave normal cells intact. 
Inspired to make a difference to the community as well as to test my chemistry lab skills, 
I challenged myself to work on the synthesis of lavendamycin derivatives in hope of finding a 
new and improved antitumor drug. The project proved to be long and challenging. Yet, I have 
learned so much from both Dr. Sarnmelson and my laboratory members. There were days when I 
could not get things to work and was very disappointed in myself. When a product was burned or 
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unable to purify, I had to either redo the reaction or change the direction of the research. 
Throughout the project, we had attempted multiple different approaches to synthesize 
quinolindione aldehyde efficiently as well as to test several solvent combinations for column 
chromatography. Through each failure, we learned from mistakes and made changes to the 
procedure to ensure the repeated experiment would be successful. As time passed, I realized the 
project was more difficult than what I initially thought. Somehow, the rewarding feeling that my 
project could potentially help millions of Americans combat against cancer kept me from giving 
up. Although I was only able to synthesize three new compounds, my contribution to the project 
would surely help other people to further the research on anticancer drugs. 
The research opportunity not only provides me a chance to positively impact my 
community, but also teaches me to incorporate my knowledge from other science classes into the 
research. The research itself is organic chemistry. However, the project could not be done 
without the help of other fields of science. In order for an anticancer drug to be marketed, it must 
pass biological studies. Thus, a sufficient knowledge in biochemistry, cellular biology and 
human physiology is necessary. Luckily, we were able to cooperate with University of Montana, 
who help us test the biological effects of the newly synthesized compounds. 
By the time the project has come to an end, I realize the project itself is more than just a 
project. It is a delightful and enjoyable journey to gain knowledge, teamwork, and most 
importantly friendship with my laboratory members that will last forever. Hopefully, the newly 
synthesized compounds will work and more people will be saved from cancer. 
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Introduction 
In the ongoing war against cancer, the goal of scientific research is to develop potent 
chemotherapy drugs that can selectively target tumor cells but are innocuous to normal cells. 
0 OH 0 
0 OH ~"NH ''oH ,,, . 




Figure 1. Mitomycin C (A) and Adriamycin (Doxorubicin) (B) 
A few examples of chemotherapy drugs are Mitomycin C and Adriarnycin (Doxorubicin). 
Both of these compounds act by blocking or stopping DNA replication and thus causing cell 
death8' 13 . Furthermore, they both possess a quinone structure. The quinone group undergoes 




Figure 2. Quinone Structure Figure 3. Structure of quinoline-5,8-dione 
Inspired by these chemotherapy drugs, our research focuses on the synthesis of antitumor 
agents that also possess a quinone, or more specifically quinoline-5,8-dione, structure. 
Quinoline-5,8-dione is known for its antifungal, antibacterial, antiparasitic, and antitumor 
activity6. Quinoline-5,8-dione comes from the parent structure-lavendarnycin. 
Lavendamycin was first isolated from the fermentation broth of Sreptomyces lavendulae 
by Balitz et al. in 19813. Its structure, as illustrated by Figure 4, was determined by Doyle et al9. 
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Lavendamycin is pentacyclic, and consists of two moieties (a quinolone-5,8-dione, and a ~­
carboline). Despite its potent biological effects on tumors and bacteria, preclinical development 
of lavendamycin was halted due to its poor aqueous solubility and nonspecific cytotoxicity 
toward human cells5•7•10. In contrast to the parent compound, quinolone-5,8-dione has low animal 
toxicity and show strong antitumor activity as well as inhibition of HIV -reverse transcriptase10' 11 • 
0 
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Figure 4. Structure of lavendamycin with P-carboline shown in red 
At micromolar concentrations, lavendamycin strongly inhibits proliferation of P388 
murine leukemia cells, MKN45 gastric carcinoma cells and WiDr colon carcinoma cells10. One 
study shows that lavendamycin is capable of attacking P-3881 leukemia cells implanted into 
BDFl mice10. Because of the lavendamycin's potent antitumor activity, researchers see a 
potential in developing anticancer drugs from its derivatives-something that is more suitable to 
the human body yet retains the potency of lavendamycin. 
Biological studies of NQOl activation by quinoline-5,8-dione have shown promising 
potentials for the development of antitumor agents that fit the research goal. NQOl stands for 
NAD(P)H:quinone oxidoreductase 1. This enzyme is expressed at high levels in cancer cells, and 
capable of catalyzing quinone-based compounds 11 • At the NQO 1 active site, quinone substrates 
bind in different orientations. Figure Sa and Sb show two ways a lavendamycin analogue can 
bind to the FAD cofactor molecule present at the NQOl active site. Figure Sc shows the 
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molecular surface of the enzyme active site, which is a hydrophobic and plastic pocket with three 
potential hydrogen-bonding residues 11 • Once activation occurs, he quinolinedione undergoes two 
electron reduction (known as the ping-pong mechanism) and activates cell death. Although the 
exact cause of apoptosis is unknown, research conjectures that it could be due to depletion of 
NADPH/NADH, coupling of oxidative phosphorylation, and/or single-strand cleavage of 
DNA12• 
Figure 5. The Binding Site ofNQOl Enzyme11 
The trick to synthesizing effective quinolone-5,8-dione is to install appropriate groups 
that can interact properly to the human cells. Previously, the binding of lavendamycin to the 
cell ' s enzyme is done via the ~-carboline attached to C-1 of quinoline-5,8-dione. Our research 
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goal is to create a new group at the C-1 position that fits the enzyme's active site better, thus 
amplifying the antitumor activity of the compound. Previously, research has focused on the 
chemistry and/or bioassays effects of R groups at position 6 and 7 of the quinolone-5,8-dione. 
The substituents mainly include alkyl, halogen, nitro groups, amino, hydroxyl, thiol and their 
derivatives6. Research by Behforouz et al. suggests that the small the R groups at C-6 and C-7, 
the higher the selectivity and metabolism rate by NQ01 6 (Table 1 and 2). This study was 
conducted to synthesize and test biological effects of different R groups at C-1 while keeping the 
R groups at C-6 and C-7 the same (hydrogen and acetamide, respectively). In addition, the study 
aims to optimize previous procedure as well as to increase the overall yield of the quinolinedione 
aldehyde, which is an intermediate molecule of the whole process. 
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Table 1. The Effects of R groups on Metabolism6 
0 
Entry R' Rl R' R4 R) Metabolism 
(~-tmol/min/mg) 
1 CH3CO H N[(CH2)4] H H 43 ± 7 
2 CH3CO H NH(CH2)20H H H 2.2 + 0.7 
3 CH3CO H OCH(CH3)CH2CH3 H H 3.9 ± 2.0 
4 CH3CO H NHCH2CH(OH)CH20H H H 36 + 6 
5 CH3CO H O(CH2)CH3 H H 6.8 + 3.5 
6 CH3CO H N[ (CH2CH2)2]NCH2Ph H H 8.7 ± 1.5 
7 CH3CO H OCH2CH3 H H 3.6 + 0.3 
8 CH3CO H OCH2CH3 H OH 21 ± 6 
9 (CH3)2CHCO H OCH3 H H 0.04 + 0.08 
10 HCO H OCH3 H H 20 + 8 
11 ClCH2CO H NH2 H H 13 + 2 
12 ClCH2CO H N[(CH2)4] H H 34 + 5 
13 2-Furyl-CO H OCH3 CH3 H 5.8 + 1.7 
14 H02C(CH2)2CO H OC4H9-n H H 5.2 + 2.6 
15 H Cl OCH2CH3 H H 6.9 + 1.1 
16 H H N[(CH2CH2)2]0 H H 103 + 8 
17 H H O(CH2)2CH(CH3)2 H OH 2.9 + 1.4 
18 H H OCH3 CH3 OH 31 + 7 
19 H H N[(CH2)4] H H 35 + 7 
20 H H NH(CH2)20H H H 26 + 4 
21 H H OCH3 H H 28 + 2 
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Table 2. The Effects of R groups on Selectivity6 
0 




1 CH3CO H N[(CH2)4] H H 2.1 
2 CH3CO H OCH(CH3)CH2CH3 H H 0.8 
3 CH3CO H NHCH2CH(OH)CH20H H H 2.8 
4 CH3CO H O(CH2)CH3 H H 1.3 
5 CH3CO H N[ (CH2CH2)2]NCH2Ph H H 0.7 
6 CH3CO H OCH2CH3 H H 1.3 
7 CH3CO H OCH2CH3 H OH 0.8 
9 HCO H OCH3 H H 1.4 
10 ClCH2CO H NH2 H H 2.1 
11 ClCH2CO H N[(CH2)4] H H 2.7 
12 H02C(CH2)2CO H OC4H9-n H H 1.6 
13 H H N[(CH2CH2)2]0 H H 9.0 
14 H H OCH3 CH3 OH 2.5 
15 H H N[(CH2)4] H H 1.1 
16 H H NH(CH2)20H H H 1.0 
17 H H OCH3 H H 2.0 
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In our research, isoxazole and isoxazoline are chosen to be the new substituent at C-1 
while is the R1 group is kept as acyl. Pharmaceutical research has shown that isoxazole and 
isoxazoline derivatives display anticonvulsant, antimicrobial, and antitumor activity1'4. In 
addition, they play a crucial role as intermediates in the organic synthesis of many heterocyclic 
pharmacological active compounds'. Already marketed drugs like Valdecoxib as COX-2 
inhibitor, Cloxacillin and Dicloxacillin as beta lactamase resistant antibiotics, which have 
isoxazole core, have been proven to be effective in respective disease scenario4 . Preliminary 
evaluation of several isoxazole derivatives demonstrates that they are excellent anticancer 
agents14. The synthesis and biological study on isoxazole and isoxazoline substituted 
quinionline-5,8-dione will give valuable insights into what functional groups can enhance the 
potency of the compound. 
N 00 




Results and Discussion 
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Scheme 1. Synthesis of 5, 7-diamino-8-hydroxy-2-methylquinoline 
In the first step, 8-hydroxy-2-methyl-5,7-dinitroquinoline (2) was produced from 
commercially available 8-hydroxyquinaldine. The product displayed two colors (green and 
yellow). Yet the 1H NMR spectra of both samples showed the same peaks. A possible 
explanation for this phenomenon is the difference in reflection and absorption of light from both 
the inner and outer surface of the compound. 
When preparing 5,7-diamino-8-hydroxy-2-methylquinoline dihydrochloride (3), the 
product was not rotovapped to dryness, but kept as a solution for the next step. In previous 
procedure, water was supposedly added in the next step. Thus, skipping over the rotovaporation 
step would save time and eliminate the chance of contamination from rotary evaporator. The 
amount of water used to wash 5,7-diamino-8-hydroxy-2-methylquinoline dihydrochloride (3) 
must be kept at minimal. Too much water seemed to intervene with the next reaction and caused 
lower yield. Sometimes, the product was rotovapped to reduce the volume of water rather than to 






Scheme 2. Synthesis of 7N-acetamido-2methylquinoline-5,8-dione 
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The reaction of 5,7N-Diacetamide-8-acetoxy-2-methylquinoline (4) often yielded over 
100%. The product must be allowed to dry for a day. Acetic anhydride should be added slowly 
for precipitate to form properly. Rushing over this step might result in lower yield. Several 
modifications were made to the preparation of 7N-acetamido-2-methylquinoline-5,8-dione (5) to 
decrease reaction time as well as to increase the percent yield. In this step, both the amount water 
and acetic acid were modified from previous procedure in hope of reducing reaction time. Water 
was used to convert potassium dichromate to chromic acid. When the amount of water was 
reduced from 43mL to llmL, the percent yield was almost the same. This could either mean the 
product was not completely extracted from the aqueous layer or the amount of water did not play 
a major role in the reaction. 
With little water, it was impossible to distinguish the layers. 50 mL of sodium 
bicarbonate was added to create an aqueous layer. Unlike water, when acetic acid was reduced 
from 45 mL to 21 mL for 3.17 mmol of 5,7N-diacetamide-8-acetoxy-2-methylquinoline (4), no 
acid was found in the organic layer. Previous, having too much acid usually caused the organic 
layer to have a red/orange color, even upon vigorous shaking. The only way to get rid of the red 
color was to let the solution sit in the reparatory funnel until the color turned clear yellow 
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(approximately one week). New sodium bicarbonate was added occasionally to make the red 
color fade faster. Without changing the sodium bicarbonate solution, it would take two weeks for 
the change in color to occur. Even when acid was reduced, solution was left in the separatory 
funnel for an extra night to ensure the removal of all acid. 
In addition, repeated experiments demonstrated that efficient yield could not be achieved 
on larger scales. The smaller the scale is, the higher the yield. Since mass production of 7N-
acetamido-2methylquinoline-5,8-dione (5) was necessary to make sufficient amount of 
isoxazoline and isoxazole, 3-5 mmol of 5,7N-diacetamide-8-acetoxy-2-methylquinoline ( 4) 
should be used in this reaction. Percent yield dropped significantly when 1 0 mmol was used. 
Se02 - H20 
Dioxane 
46% 
Scheme 3. Synthesis of oxime 
7N-Acetamido-2-formylquinoline-5,8-dione (6) proved to be the most challenge step. 
Many procedures called for a 2 or 3-necked round bottomed flask. Although having extra necks 
made it easier to add selenium and water during the reflux, they were unnecessary. The solution 
vapor could easily get trapped in the rubber stoppers, leading to low yield and contamination. In 
addition, this reaction should not be done on a large scale due to high impurities and low yield. 
The ratio of selenium dioxide to 7N-acetamido-2-methylquinoline-5,8-dione (5) should be 1.2~3 
to 1. When the ratio was over 2:1 , product had a brown/red color which was indicative of 
impurities. 
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Previous procedure called for Celite cake to get rid of selenium. However, it was 
inefficient in our study since the product seemed to be trapped in the Celite cake and had an 
orange/brown color at the end. Column was attempted, but was ineffective. The majority of the 
product was lost in the column. To replace the Celite cake, a Celite column made with a glass 
pipette and a cotton ball. Because the column might not be packed tightly, air was not advised to 
use. The organic layer was washed with sodium chloride and sodium bicarbonate to get rid of 
extra selenium and acid. Drying the organic layer with magnesium sulfate might be skipped if 
high vac was used. This change in procedure avoided the loss of the product from transferring 
between glassware. 
Oxime (7) had a very poor organic solubility. When recrystallizing with ethyl acetate, the 
product was not completely dissolved. Thus, purification was not achieved and column 
chromatography was attempted. Due to the poor recovery from column, using clean starting 
materials was the best way to achieve pure product. 
0 0 o¢ NaOCI, CH2CI2 0 )l~ N/- I ~ _)lN 
I 
0 N,OH H 0 N-o 
7 71% 8 
0 0 
o¢ 0 
_)lN N/- NaOCI, CH2CI2 _)lN o -
H 0 ~ 'OH ~0/ H 0 
7 59% 9 
Scheme 4. Synthesis of isoxazoline and isoxazole 
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Isoxazoline (8) and isoxazole (9) were not as tricky as the aldehyde (6) substituent. The 
first few drops of bleach were added very slowly to ensure the reaction occurs favorably. 
Oftentimes, the process took more than 30 minutes (usually 1 hour on average). Vigorous stirring 
was necessary. Weak stirring resulted in lower yield and the color remained yellowish green. 
Good isoxazole and isoxazoline should have bright yellow color. Because recrystallization did 
not seem to work, column chromatography was the only way to purify the product, which 
resulted in lower yield. 
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Experimental 
Preparation of 8-Hydroxy-2-methyl-5,7-dinitroquinoline (2) 
In a 125 mL Erlenmeyer flask cooled by ice-water bath, 3 mL of sulfuric acid and 2.0 g 
(12.3 mmol) of 8-hydroxyquinaldine were combined and stirred. Ice cold concentrated nitric acid 
(5 mL) was added dropwise over 30 minutes. The solution was brought to room temperature and 
stirred for an additional one hour. The dark brown solution was added to 100 mL of ice/water 
and the bright yellow precipitate was collected via vacuum filtration. The solid was washed with 
water and dried overnight to yield 3.07 g (59%). 1H NMR (DMSO-d6) 8 2.95 (s, 3H), 8.15 (d, J = 
8.9 Hz, lH), 9.21 (s, lH), 9.67 (d, J = 8.9 Hz, 1H). 
Preparation of 5,7-Diamino-8-hydroxy-2-methylquinoline dihydrochloride (3) 
In a 500mL Parr hydrogenation bottle, 8-hydroxy-2-methyl-5,7-dinitroquinoline (9.0 g, 
6.1 mmol) and 5% Pd/C (2.0 g, 0.9 mmol) were added to a solution made with 15 rnL of 12M 
HCl and 135 mL of water. The mixture was shaken on the hydrogenerator for 18h at 38psi. The 
dark red solution was vacuumed filtered and washed with distilled water. The filtrate was kept 
for the next step. 
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In a 500 mL round-bottomed flask containing 5,7-diamino-8-hydroxy-2-methylquinoline 
dihydrochloride solution, sodium acetate (30.0 g, 370 mmol) and sodium sulfite (15.0 g, 119 
mmol) were added and stirred. The solution was placed in an ice-water bath, and 88 mL of acetic 
anhydride was added dropwise over an hour. The solution was stirred for an additional 1.5h and 
the yellow-white precipitate was collected via vacuum filtration to yield 11.38 g (99%). 1H NMR 
(DMSO-d6) 8 2.14 (s, 3H), 2.15 (s, 3H), 2.41 (s, 3H), 2.58 (s, 3H), 7.35 (d, J = 8.6 Hz, 1H), 8.23 
(d, J = 8.6 Hz, 1H), 8.31 (s, 1H), 9.76 (s, 1H), 10.02 (s, 1H) 




In a 100 mL round-bottomed flask, methanol (57 mL), water (5 mL) and 5,7N-
Diacetamide-8-acetoxy-2-methylquinoline (1.0 g, 3. 17 mmol) were combined and refluxed for 
30 minutes. The solution was rotovapped to dryness. The dried compound was dissolved in 
glacial acetic acid (21 mL ), and then combined with chromic acid made with potassium 
dichromate (2.8 g, 9.51 mmol) and water (11.3 ml). The solution was vigorously stirred for 8h. 
5% Sodium bicarbonate (50 mL) was added to the dark red solution before it was extracted with 
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dichloromethane (70 mL, 5x25 mL). The combined organic layer was washed with 5% sodium 
bicarbonate (4x25mL). The yellow solution was dried with magnesium sulfate and filtered 
through a funnel stuffed with cotton ball. The filtrate was rotovapped to dryness to recover 0.38 
g (52%). 1H NMR (CDCb) 8 2.30 (s, 3H), 2.75 (s, 3H), 7.55 (d, J = 8.0 Hz, 1H), 7.90 (s, lH), 
8.29 (d, 8.0 Hz, lH), 8.38 (br s, lH). 
Preparation of 7N-Acetamido-2-formylquinoline-5,8-dione (6) 
Dioxane was dried and distilled prior to reaction. 7N-Acetamido-2-methylquinoline-5,8-
dione (0.23 g, 1.00 mmol), selenium dioxide (0.13 g, 1.22 mmol), and dioxane (3.5 mL) were 
added to a 25 mL round-bottomed flask. The solution was gently refluxed under argon until the 
mixture became homogenous. Water (0.15 mL) was then added and the reaction ran for 16 h. 
Addition of minimal amount of selenium dioxide and water were used to keep solution from 
drying and to drive reaction to completion, which was checked by chromatography (DCM/ethyl 
acetate 50:50). Two glass pipettes were plugged with cotton balls and filled with celite to make a 
celite column. The black solution was poured into the columns and washed with 100 mL of 
DCM. The solution was transferred to a separatory funnel and washed with NaCl (1x15 mL) and 
5% sodium bicarbonate (5x20 mL). The yellow solution was dried with magnesium sulfate and 
filtrated through a cotton plugged funnel. Rotovaporation of the product yielded 0.11 g ( 46% ). 
1H NMR (CDCh) 8 2.33 (s, 3H), 8.05 (s, 1H), 8.31 (d, J = 8.0 Hz, IH), 8.43 (br s, IH), 8.62 (d, J 
= 8.0 Hz, IH), 10.29 (s, IH) 
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Preparation of 7N-acetamido-5,8-dione-quinolyl-2-aldoxime (7) 
In a 25 mL round-bottomed flask, 7N-Acetamido-2-formylquinoline-5,8-dione (100.0 
mg, 0.41 mmol), hydroxylamine hydrochloride (31.6 mg, 0.454 mmol) and sodium acetate (54.2 
mg, 0.66 mmol) were added to a solution of ethanol:water (4: 1mL). The solution was stirred 
vigorously for 16h and then stirred in an ice-water bath for an additional 2h. Vacuum filtration of 
the product yielded 0.056 g (52%). 1H NMR (DMSO-d6) 8 2.27 (s, 3H), 7.74 (s, 1H), 8.19 (d, J = 




In a 25 mL round-bottomed flask, 7N-acetamido-5,8-dione-quinoline-2-aldoxime (0.260 
g, 1.00 mmol), 3,3-dimethyl-1butene (0.422 g, 5.01 mmol) and 10 mL ofDCM were combined, 
stirred, and then cooled to 0 °C. Bleach (sodium hypochlorte, 0.7 M, 3.0 mL, 2.1 mmol) was 
added dropwise over 30min. The solution was brought to room temperature and stirred 
vigorously for 8h. Extraction with DCM (4x10 mL) gave a yellow solution. It was dried with 
sodium sulfate and filtrated through a cotton plugged funnel. Rotovaporation of the product 
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. . I y1elded 0.12 g (71%). H NMR (CDCh) o 1.00 (s, 9H), 2.31 (s, 3H), 3.34 (dd, J = 18.0, 9.9 Hz, 
1H), 3.49 (dd, J = 18.0, 11.4 Hz, 1H), 4.59 (dd, J = 11.4, 9.9 Hz, 2H), 7.96 (s, 1H), 8.36 (br s, 
lH), 8.38 (d, J = 8.4 Hz, 1H), 8.41 (s, J = 8.4 Hz, lH) 









In a 50mL round-bottomed flask, 7N-acetamido-5,8-dione-quinoline-2-aldoxime (0.132 
g, 0.509 mmol), methyl propargyl ether (0.303 g, 2.55 mmol) and 1 OmL of DCM were 
combined, stirred, and then cooled to 0 °C. Bleach (sodium hypochlorite, 0.7 M, 3.0 mL, 2.1 
mmol) was added dropwise over 30min. The solution was brought to room temperature and 
stirred vigorously for 8h. Extraction with DCM ( 4x 1 OmL) gave a yellow solution. It was dried 
with sodium sulfate and filtrated through a cotton plugged funnel. Rotovaporation of the product 
yielded 0.10 g (59%). 1H NMR (CDCh) o 2.33 (s, 3H), 3.48 (s, 3H), 4.64 (s, 2H), 7.14 (s, 1H), 
7.99 (s, lH), 8.39 (br s, 1H), 8.48 (d, J = 8.0 Hz, lH), 8.54 (d, J = 8.0 Hz, 1H) 
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1H NMR spectrum of 8-Hydroxy-2-methyl-5, 7-dinitroquinoline 
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1H NMR spectrum of 5, 7-Diacetamido-8-acetoxy-2-methylquinoline 
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1H NMR spectrum of 5,7N-Diacetamido-8-hydroxy-2-methylquinoline 
Nguyen 25 
1H NMR spectrum of 7N-Acetamido-2-methylquinoline-5,8-dione 
Nguyen 26 
1H NMR spectrum of 7N-acetamido-2-formylquinoline-5,8-dione 
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1H NMR spectrum of 7N-acetamido-5,8-dione-quinoline-2-aldoxime 
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1H NMR spectrum of 7N-Acetamido-2-[5-(l,l-dimetbylethyl)-4,5-dibydro-3-isoxazolyl]-
quinoline-5,8-dione (8) 
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